In response to the recently published clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic, the ACR is hosting a virtual town hall for the rheumatology community on Wednesday, May 6, at 7–8 p.m. EDT, to review the recommendations. Moderated by ACR President Ellen M. Gravallese, MD, and ACR…
3 U.S. Children with COVID-19 Have Rare Inflammatory Syndrome
CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters. All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University…
Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule
(Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study. Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy…
U.S. Supreme Court Rules for Insurers over $12 billion Obamacare Claims
WASHINGTON (Reuters)—The U.S. Supreme Court ruled in favor of health insurers seeking $12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans. The 8–1 ruling authored by liberal Justice Sonia Sotomayor paves the way for a significant one-time…
Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients
(Reuters)—On April 27, Regeneron Pharmaceuticals Inc. and Sanofi SA said on Monday that their arthritis drug sarilumab (Kevzara) may only help the sickest patients with COVID-19, dampening hopes that the therapy could potentially reach a larger pool of patients with the disease. The drugmakers said they would test high doses of sarilumab only in critically…
U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19
(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…
3 Ways to Advance the Med-Peds Role in Rheumatology
Research into training and careers for Med-Peds—internal medicine-pediatrics trained rheumatologists–will help pinpoint how this unique specialty can support patient needs and address rheumatology workforce shortages…
Systemic Sclerosis Patients May Benefit from Targeted Stroke Screening
Patients with systemic sclerosis (SSc) may benefit from targeted stroke screening or prevention therapies. A recent study revealed SSc may be independently associated with stroke, finding the risk of stroke was 20–30% higher in SSc patients than healthy controls…
Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19
Humans may fear change as a general rule, but we’re adaptable when we need to be. In this era of COVID-19 and social distancing, medical practices and payers are adapting to an increased use of telemedicine, which enables providers to see their patients without being in a room with them. To cope, the Centers for…
On Pandemics & Uncertainty: One Rheumatologist’s Story
As the mystery solvers, we are supposed to be comfortable with the unknown, but how does that translate when COVID-19 hits home? A rheumatologist contracts COVID-19.
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 309
- Next Page »